Antibody-Drug Conjugates SOT102

SOTIO’s lead candidate from its ADC pipeline is SOT102, targeting Claudin18.2 (CLDN18.2). 

SOT102 has demonstrated potent anti-tumor efficacy in vitro and in vivo and, due to the proprietary site-specific sortase mediated antibody coupling (SMAC) conjugation platform of NBE-Therapeutics, has superior manufacturing properties including stability and aggregation propensity. Learn more here.

In 2022, SOTIO initiated the Phase 1/2 CLAUDIO-01 clinical trial studying SOT102 in patients with gastric and pancreatic cancer. CLAUDIO-01 (EudraCT number: 2021-005873-25) is a first in human, open label, multicenter clinical trial to assess the safety and preliminary efficacy of SOT102 in monotherapy and in combination with established standard of care therapies (SoC).

The trial will enroll patients with gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinoma across sites in Belgium, the Czech Republic, France, Spain and the USA.